Boston Scientific (NYSE:BSX) Reaches New 1-Year Low – Here’s Why

Boston Scientific Corporation (NYSE:BSX) reached a new 52-week low on Tuesday . The stock traded as low as $69.52 and last traded at $71.8760, with a volume of 11649572 shares traded. The stock had previously closed at $71.35.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Company actions that may support the share price: Boston Scientific negotiated a new $3.0 billion revolving credit facility (matures 2031), expanded its share‑repurchase authorization to $5.0 billion, and added two senior healthcare/finance leaders to the board — moves that can bolster liquidity and signal confidence in capital returns. Is Boston Scientific (BSX) Balancing Buybacks and Litigation or Masking Deeper Electrophysiology Risks?
• Neutral Sentiment: Options activity: traders bought ~23,040 put contracts on Monday — roughly a 27% increase vs. typical daily put volume — indicating elevated hedging or bearish interest but not a definitive directional signal by itself.
• Negative Sentiment: Legal and regulatory risk escalating: multiple law firms (Rosen, Levi & Korsinsky, Robbins, Bronstein, Schall, Faruqi & Faruqi) have filed or announced investigations and class actions on behalf of BSX investors covering the July 23, 2025–Feb 3, 2026 period; lead‑plaintiff deadlines have been set (May 4, 2026 in several notices). The suits and media coverage cite a Class I recall of the AXIOS Stent & Delivery System, a federal probe of disclosures/product safety, and allegations of misleading statements about the U.S. electrophysiology business — risks that could lead to settlements, fines, or reputational damage and weigh on earnings and cash flow. Shareholders of Boston Scientific Corporation Should Contact Levi & Korsinsky Boston Scientific Recall And Lawsuits Test Earnings Power And Capital Plans

Wall Street Analyst Weigh In

A number of analysts recently commented on BSX shares. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 price target on shares of Boston Scientific in a research note on Friday, February 6th. Needham & Company LLC dropped their target price on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Wells Fargo & Company lowered their price objective on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Finally, Truist Financial decreased their target price on Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Stock Up 0.7%

The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company has a market capitalization of $106.66 billion, a PE ratio of 37.05, a P/E/G ratio of 1.00 and a beta of 0.69. The company’s 50-day moving average is $84.55 and its 200 day moving average is $94.24.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is owned by corporate insiders.

Institutional Trading of Boston Scientific

A number of hedge funds have recently bought and sold shares of BSX. Brighton Jones LLC grew its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the period. Savant Capital LLC grew its position in shares of Boston Scientific by 4.1% during the 2nd quarter. Savant Capital LLC now owns 21,236 shares of the medical equipment provider’s stock valued at $2,281,000 after acquiring an additional 834 shares during the period. AE Wealth Management LLC increased its stake in shares of Boston Scientific by 6.9% in the 2nd quarter. AE Wealth Management LLC now owns 19,866 shares of the medical equipment provider’s stock worth $2,134,000 after purchasing an additional 1,280 shares in the last quarter. Prospera Financial Services Inc raised its holdings in Boston Scientific by 17.1% in the 2nd quarter. Prospera Financial Services Inc now owns 9,251 shares of the medical equipment provider’s stock worth $994,000 after purchasing an additional 1,348 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Boston Scientific in the second quarter worth about $249,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.